Abstract 1603P
Background
The Cancer Aging Research Group (CARG) developed a prediction tool for chemotherapy-related toxicity in older cancer patients. Evidence has put forward the crucial impact of a patient's race on the type and extent of chemotherapy toxicity. Therefore, the CARG model requires validation in different populations before its general application. In this study, we aim to evaluate the predictive value of the CARG model in Iranian patients as a representative of the Middle East North Africa (MENA) region population.
Methods
This prospective longitudinal study involved patients 65 years of age and older starting a new cytotoxic chemotherapy regimen. We did general (including Karnofsky performance status, KPS) and CARG-based assessments before chemotherapy. Chemotherapy toxicities were recorded during chemotherapy courses. The predictive values of CARG and KPS were evaluated using the area under the receiver-operating characteristic curve (AUC-ROC). Chemotherapy toxicities were sub-analyzed per hematologic and nonhematologic types.
Results
This study examined 76 patients across 456 chemotherapy cycles. The mean age was 71 years. Treatment was palliative in 46 patients (60.5%). Chemotherapy-related toxicity was reported in 23.6% of patients. There was no correlation between CARG risk groups and total chemotherapy toxicity (15% low-risk, 31% intermediate-risk, 20% high-risk, P = .32). Regarding CARG model, the corresponding AUC-ROC was 0.56 (95% CI, 0.40–0.69) for total toxicity, 0.67 (95% CI, 0.48–0.78) for hematologic toxicity, and 0.39 (95% CI, 0.21–0.66) for nonhematologic toxicity. Regarding physician-rated KPS, the corresponding AUC-ROC was 0.56 (95% CI, 0.40–0.72) for total toxicity, 0.55 (95% CI, 0.37–0.72) for hematologic toxicity, and 0.61 (95% CI, 0.37–0.86) for nonhematologic toxicity.
Conclusions
CARG model had an acceptable ability to predict hematologic toxicities; however, its efficacy for total and nonhematologic toxicities was limited.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ahmad Ameri.
Funding
Shahid Beheshti University of Medical Sciences (SBUMS).
Disclosure
All authors have declared no conflicts of interest.